

## **REMARKS**

Reconsideration of the application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 34 to 38, 40 to 43, 50 and 51 and new claim 52, all other claims being cancelled.

Claims 41 and 51 were rejected under 35 U.S.C. 112, first paragraph as lacking support for the term “pharmaceutical preparation in the form of solution”.


Applicants respectfully traverse this ground of rejection since claim 51 now calls administering a compound of claim 43 without reference to a solution. Claim 41 calls for the compound of claim 43 to be dissolved in an appropriate medium which medium could be apyrogenic sterile water in claim 42 not objected to by the Examiner or other appropriate medium. New claim 52 points out a number of forms of the pharmaceutical compositions as disclosed in the paragraph that begins on the last two lines of page 7 of the specification. Therefore, withdrawal of this ground of rejection is requested.

All the claims were rejected under 35 U.S.C. 112, second paragraph as being indefinite. Claim 38 has been amended to point out that the compound is administered parenterally. Claim 50 recites a pharmaceutical carrier and claim 51 now recites administering the compound and does not refer to a pharmaceutical preparation. Claim 43 has been amended to

incorporate the substituents into the structural formula and to insert the semi-colon. Therefore, the amended claims comply with 35 U.S.C. 112 and withdrawal of these grounds of rejection is requested.

In view of the amendments to the claims and the above remarks, it is believed that the claims point out Applicants' patentable contribution. If there are any minor problems, the Examiner is requested to telephone the undersigned so they may be corrected by Examiner's Amendment.

Respectfully submitted,  
Hedman and Costigan

  
Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel. 212 302 8989

CAM:mlp  
Enclosures